BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 26408669)

  • 1. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
    Jin GH; Hirano T; Murakami M
    Int Immunol; 2008 Jun; 20(6):783-9. PubMed ID: 18448458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.
    Han KH; Kim KW; Yan JJ; Lee JG; Lee EM; Han M; Cho EJ; Kang SS; Lim HJ; Koo TY; Ahn C; Yang J
    BMC Urol; 2016 Jan; 16():2. PubMed ID: 26772545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
    Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
    Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
    Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
    J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory T cell production capacity of these cells in vivo.
    Jeong YJ; Kim JH; Hong JM; Kang JS; Kim HR; Lee WJ; Hwang YI
    Immunobiology; 2014 Jul; 219(7):554-64. PubMed ID: 24698552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
    J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
    Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
    J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
    Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
    J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.
    Takeda Y; Azuma M; Matsumoto M; Seya T
    J Exp Clin Cancer Res; 2016 Sep; 35(1):143. PubMed ID: 27619885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
    Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
    J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
    Kamimura D; Sawa Y; Sato M; Agung E; Hirano T; Murakami M
    J Immunol; 2006 Jul; 177(1):306-14. PubMed ID: 16785526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.